Hot flashes on anastrozole and Zoladex: what the evidence shows

What's this video probably claiming?

Based on the hashtags and creator context, @talkbreastie2me is almost certainly sharing a personal experience of hot flashes as a side effect of hormone suppression therapy, specifically the combination of Zoladex (goserelin) and anastrozole. This is a standard endocrine suppression regimen used in premenopausal women with hormone receptor-positive breast cancer, including metastatic cases. The creator appears to be documenting life in treatment, likely normalizing the vasomotor symptoms that come with chemical or surgical ovarian suppression. The video probably frames hot flashes as a direct, expected consequence of dropping estrogen levels to near-zero, which is pharmacologically accurate. What we can't verify yet is whether any claims are made about managing those symptoms, and whether any proposed solutions stray into territory that contradicts the oncology team's guidance. That's the part that warrants scrutiny.

What does the science actually show?

Goserelin (Zoladex) is an LHRH agonist that suppresses ovarian estrogen production. Combined with anastrozole, an aromatase inhibitor that blocks peripheral estrogen synthesis, the combination drives estradiol levels to post-menopausal or sub-menopausal ranges. The SOFT and TEXT trials (Francis et al., 2015, New England Journal of Medicine) demonstrated that ovarian suppression plus exemestane or anastrozole reduced breast cancer recurrence compared to tamoxifen alone in premenopausal women, but vasomotor symptoms, meaning hot flashes, night sweats, and sleep disruption, were significantly worse. In the TEXT trial, roughly 90 percent of women on OFS plus aromatase inhibitor reported hot flashes versus approximately 78 percent on tamoxifen. That is not a small difference when you are living it every day. Estrogen is the primary thermoregulatory modulator in women, and removing it abruptly, whether chemically or surgically, dysregulates the hypothalamic temperature set point.

Where does the social media noise diverge from clinical reality?

The problem with breast cancer content on TikTok is not usually the creator. It is the comments section and the algorithmic rabbit hole that follows. Videos like this one attract well-meaning suggestions about phytoestrogens, black cohosh, bioidentical hormones, and testosterone supplementation to manage hot flashes. Some of those suggestions carry real oncological risk. Hormone replacement therapy, including estrogen or combined HRT, is generally contraindicated in hormone receptor-positive breast cancer patients. Black cohosh has weak and inconsistent evidence (Leach and Moore, 2012, Cochrane Database), and the phytoestrogenic compounds in soy and flaxseed, while probably low-risk at dietary doses, have not been validated in metastatic HR-positive populations. The testosterone angle is particularly fraught here. TRT in women with HR-positive cancer is not an established standard of care, and testosterone can aromatize to estrogen, which is precisely what this drug combination is trying to suppress.

What should you actually know?

If you are on Zoladex plus anastrozole and the hot flashes are genuinely affecting your quality of life, there are evidence-backed non-hormonal options. Venlafaxine 37.5 to 75 mg daily has the most consistent trial data for vasomotor symptom reduction in breast cancer patients (Loprinzi et al., 2000, Lancet). Gabapentin at 300 mg three times daily also showed meaningful symptom reduction versus placebo in a randomized trial (Pandya et al., 2005, Journal of Clinical Oncology). Oxybutynin 2.5 to 5 mg twice daily is emerging as a practical option with a reasonable side effect profile. None of these require you to compromise your cancer treatment. What you should not do is self-manage with hormonal supplements, including testosterone gels or pellets, without explicit sign-off from your oncologist. The stakes in hormone receptor-positive metastatic disease are too high for improvisation based on a TikTok comment thread.